Diseases of the neurovascular unit, consisting of the endothelial vasculature and supporting cells, are incredibly prevalent in patients. Two such diseases, stroke and traumatic brain injury (TBI), share major pathological similarities, with acute and chronic pathways leading to neurodegeneration. In particular, the neuroinflammatory aspect of stroke and TBI pathology has been shown to contribute significantly to worsening outcomes. Fortunately, neuroinflammation also offers an accessible therapeutic target. Minimal treatment options currently exist for either disease, but stem cell-based therapies have demonstrated great promise in offering neuroprotection and encouraging neuroregeneration after the initial insult. Stem cells have been shown to mitigate chronic neuroinflammation as well as modulate peripheral inflammation via the spleen. Additionally, stem cells have been demonstrated to preferentially migrate to the spleen when injected after a neurovascular injury. This further validates the notion that stem cells are inflammation-honing “biologics” and confer their neuroprotection in large by ameliorating the global inflammatory response. Current research investigations are focused on understanding these cell death and neural repair processes in an effort to utilize the preclinical findings toward efficient strategies designed to employ stem cell therapies as a treatment for stroke, TBI, and other neurovascular diseases. Here, we provide scientific evidence supporting the use of stem cell therapy for neurovascular diseases through the cells’ robust ability to sequester the inflammatory response associated with the secondary cell death that plagues both stroke and TBI.
- Stem cells
- Neurovascular disease
- Neurovascular unit
- Ischemic stroke
- Traumatic brain injury
- Regenerative medicine
This is a preview of subscription content, access via your institution.
Starke RM, et al. Developments in neurovascular diseases and treatments. ScientificWorldJournal. 2015;2015:608607.
Adamson J, Beswick A, Ebrahim S. Is stroke the most common cause of disability? J Stroke Cerebrovasc Dis. 2004;13(4):171–7.
Ovbiagele B, Nguyen-Huynh MN. Stroke epidemiology: advancing our understanding of disease mechanism and therapy. Neurotherapeutics. 2011;8(3):319–29.
Sacco RL, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(7):2064–89.
Reid MW, Velez CS. Discriminating military and civilian traumatic brain injuries. Mol Cell Neurosci. 2015;66(Pt B):123–8.
Helmick KM, et al. Traumatic brain injury in the US military: epidemiology and key clinical and research programs. Brain Imaging Behav. 2015;9(3):358–66.
Ellis MJ, et al. Psychiatric outcomes after pediatric sports-related concussion. J Neurosurg Pediatr. 2015;16(6):709–18.
Morgan CD, et al. Predictors of postconcussion syndrome after sports-related concussion in young athletes: a matched case-control study. J Neurosurg Pediatr. 2015;15(6):589–98.
Virji-Babul N, et al. Changes in functional brain networks following sports-related concussion in adolescents. J Neurotrauma. 2014;31(23):1914–9.
Coronado VG, et al. Surveillance for traumatic brain injury-related deaths—United States, 1997-2007. MMWR Surveill Summ. 2011;60(5):1–32.
Masel BE, DeWitt DS. Traumatic brain injury: a disease process, not an event. J Neurotrauma. 2010;27(8):1529–40.
McAllister TW. Neurobiological consequences of traumatic brain injury. Dialogues Clin Neurosci. 2011;13(3):287–300.
Tajiri N, et al. A nuclear attack on traumatic brain injury: sequestration of cell death in the nucleus. CNS Neurosci Ther. 2016;22(4):306–15.
Lok J, et al. Targeting the neurovascular unit in brain trauma. CNS Neurosci Ther. 2015;21(4):304–8.
Kumar A, Loane DJ. Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. Brain Behav Immun. 2012;26(8):1191–201.
Nguyen H, et al. Growth factor therapy sequesters inflammation in affording neuroprotection in cerebrovascular diseases. Expert Rev Neurother. 2016;16(8):915–26.
Acosta SA, et al. Alpha-synuclein as a pathological link between chronic traumatic brain injury and Parkinson’s disease. J Cell Physiol. 2015;230(5):1024–32.
Kang X, et al. delta-Opioid receptors protect from anoxic disruption of Na+ homeostasis via Na+ channel regulation. Cell Mol Life Sci. 2009;66(21):3505–16.
Wang Y, Qin ZH. Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis. 2010;15(11):1382–402.
Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 2002;1(6):383–6.
Lozano D, et al. Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities. Neuropsychiatr Dis Treat. 2015;11:97–106.
Xiong XY, Liu L, Yang QW. Functions and mechanisms of microglia/macrophages in neuroinflammation and neurogenesis after stroke. Prog Neurobiol. 2016;142:23–44.
Tajiri N, et al. Suppressed cytokine expression immediatey following traumatic brain injury in neonatal rats indicates an expeditious endogenous anti-inflammatory response. Brain Res. 2014;1559:65–71.
Kumar RG, Boles JA, Wagner AK. Chronic inflammation after severe traumatic brain injury: characterization and associations with outcome at 6 and 12 months postinjury. J Head Trauma Rehabil. 2015;30(6):369–81.
Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173–85.
Hu X, et al. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke. 2012;43(11):3063–70.
Shlosberg D, et al. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol. 2010;6(7):393–403.
Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease—a double-edged sword. Neuron. 2002;35(3):419–32.
Griffiths MR, Gasque P, Neal JW. The multiple roles of the innate immune system in the regulation of apoptosis and inflammation in the brain. J Neuropathol Exp Neurol. 2009;68(3):217–26.
Srinivasan K, et al. Untangling the brain's neuroinflammatory and neurodegenerative transcriptional responses. Nat Commun. 2016;7:11295.
Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol. 2010;87(5):779–89.
Andrade AF, et al. The pathophysiological mechanisms following traumatic brain injury. Rev Assoc Med Bras (1992). 2009;55(1):75–81.
Abate MG, et al. Early derangements in oxygen and glucose metabolism following head injury: the ischemic penumbra and pathophysiological heterogeneity. Neurocrit Care. 2008;9(3):319–25.
Wu HM, et al. Redefining the pericontusional penumbra following traumatic brain injury: evidence of deteriorating metabolic derangements based on positron emission tomography. J Neurotrauma. 2013;30(5):352–60.
Heiss WD. The ischemic penumbra: how does tissue injury evolve? Ann N Y Acad Sci. 2012;1268:26–34.
Ajmo CT Jr, et al. The spleen contributes to stroke-induced neurodegeneration. J Neurosci Res. 2008;86(10):2227–34.
Richart CH, Hayashi CY, Hedin M. Phylogenomic analyses resolve an ancient trichotomy at the base of Ischyropsalidoidea (Arachnida, Opiliones) despite high levels of gene tree conflict and unequal minority resolution frequencies. Mol Phylogenet Evol. 2016;95:171–82.
Writing Group, M, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–360.
Haas S, Weidner N, Winkler J. Adult stem cell therapy in stroke. Curr Opin Neurol. 2005;18(1):59–64.
Tang G, et al. Mesenchymal stem cells maintain blood-brain barrier integrity by inhibiting aquaporin-4 upregulation after cerebral ischemia. Stem Cells. 2014;32(12):3150–62.
Wei ZZ, et al. Intranasal delivery of bone marrow mesenchymal stem cells improved neurovascular regeneration and rescued neuropsychiatric deficits after neonatal stroke in rats. Cell Transplant. 2015;24(3):391–402.
Stone LL, Grande A, Low WC. Neural repair and neuroprotection with stem cells in ischemic stroke. Brain Sci. 2013;3(2):599–614.
Gopurappilly R, et al. Stem cells in stroke repair: current success and future prospects. CNS Neurol Disord Drug Targets. 2011;10(6):741–56.
Wang W, et al. Hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke: mechanisms, models, and biomarkers. Mol Neurobiol. 2015;52(3):1572–9.
Acosta SA, et al. Combination therapy of human umbilical cord blood cells and granulocyte colony stimulating factor reduces histopathological and motor impairments in an experimental model of chronic traumatic brain injury. PLoS One. 2014;9(3):e90953.
Lin D, et al. Brain-derived neurotrophic factor signaling pathway: modulation by acupuncture in telomerase knockout mice. Altern Ther Health Med. 2015;21(6):36–46.
Siddiq I, et al. Treatment of traumatic brain injury using zinc-finger protein gene therapy targeting VEGF-A. J Neurotrauma. 2012;29(17):2647–59.
Kim HJ, Lee JH, Kim SH. Therapeutic effects of human mesenchymal stem cells on traumatic brain injury in rats: secretion of neurotrophic factors and inhibition of apoptosis. J Neurotrauma. 2010;27(1):131–8.
Ruscher K, et al. Inhibition of CXCL12 signaling attenuates the postischemic immune response and improves functional recovery after stroke. J Cereb Blood Flow Metab. 2013;33(8):1225–34.
Lanfranconi S, et al. Growth factors in ischemic stroke. J Cell Mol Med. 2011;15(8):1645–87.
Kim J, et al. Developmental and degenerative modulation of brain-derived neurotrophic factor transcript variants in the mouse hippocampus. Int J Dev Neurosci. 2014;38:68–73.
Isgor C, et al. Expansion of the dentate mossy fiber-CA3 projection in the brain-derived neurotrophic factor-enriched mouse hippocampus. Neuroscience. 2015;288:10–23.
Gage FH. Mammalian neural stem cells. Science. 2000;287(5457):1433–8.
Ming GL, Song H. Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron. 2011;70(4):687–702.
Merson TD, Bourne JA. Endogenous neurogenesis following ischaemic brain injury: insights for therapeutic strategies. Int J Biochem Cell Biol. 2014;56:4–19.
Liska MG, et al. Implication of biobridge concept in stem cell therapy for ischemic stroke. J Neurosurg Sci. 2016;61:173–9.
Tajiri N, et al. Stem cell recruitment of newly formed host cells via a successful seduction? Filling the gap between neurogenic niche and injured brain site. PLoS One. 2013;8(9):e74857.
Zhang Y, et al. Systemic administration of cell-free exosomes generated by human bone marrow derived mesenchymal stem cells cultured under 2D and 3D conditions improves functional recovery in rats after traumatic brain injury. Neurochem Int. 2016; doi:10.1016/j.neuint.2016.08.003.
Hosseini SM, et al. Combination cell therapy with mesenchymal stem cells and neural stem cells for brain stroke in rats. Int J Stem Cells. 2015;8(1):99–105.
Liu SJ, et al. Co-grafting of neural stem cells with olfactory en sheathing cells promotes neuronal restoration in traumatic brain injury with an anti-inflammatory mechanism. J Neuroinflammation. 2014;11:66.
Barnett SC, Riddell JS. Olfactory ensheathing cells (OECs) and the treatment of CNS injury: advantages and possible caveats. J Anat. 2004;204(1):57–67.
Fairless R, Barnett SC. Olfactory ensheathing cells: their role in central nervous system repair. Int J Biochem Cell Biol. 2005;37(4):693–9.
Seyfried DM, et al. Mannitol enhances delivery of marrow stromal cells to the brain after experimental intracerebral hemorrhage. Brain Res. 2008;1224:12–9.
Bilen S, et al. Treatment efficacy with bone marrow derived mesenchymal stem cells and minocycline in rats after cerebral ischemic injury. Stem Cell Rev. 2013;9(2):219–25.
Nudi ET, et al. Combining enriched environment, progesterone, and embryonic neural stem cell therapy improves recovery after brain injury. J Neurotrauma. 2015;32(14):1117–29.
Ma Z, et al. Effects of umbilical cord mononuclear cells transplantation combined with hyperbaric oxygen therapy on hypoxic-ischemic brain damage in neonatal rats. Zhongguo Dang Dai Er Ke Za Zhi. 2015;17(7):736–40.
Geng CK, et al. Effect of mesenchymal stem cells transplantation combining with hyperbaric oxygen therapy on rehabilitation of rat spinal cord injury. Asian Pac J Trop Med. 2015;8(6):468–73.
Tu Y, et al. Combination of temperature-sensitive stem cells and mild hypothermia: a new potential therapy for severe traumatic brain injury. J Neurotrauma. 2012;29(14):2393–403.
Gao S, et al. Differentiation of human adipose-derived stem cells into neuron-like cells which are compatible with photocurable three-dimensional scaffolds. Tissue Eng Part A. 2014;20(7–8):1271–84.
Moshayedi P, et al. Systematic optimization of an engineered hydrogel allows for selective control of human neural stem cell survival and differentiation after transplantation in the stroke brain. Biomaterials. 2016;105:145–55.
Seifert HA, et al. A transient decrease in spleen size following stroke corresponds to splenocyte release into systemic circulation. J Neuroimmune Pharmacol. 2012;7(4):1017–24.
Acosta SA, et al. Intravenous bone marrow stem cell grafts preferentially migrate to spleen and abrogate chronic inflammation in stroke. Stroke. 2015;46(9):2616–27.
Mohamed IN, et al. Role of inflammasome activation in the pathophysiology of vascular diseases of the neurovascular unit. Antioxid Redox Signal. 2015;22(13):1188–206.
Famakin BM. The immune response to acute focal cerebral ischemia and associated post-stroke immunodepression: a focused review. Aging Dis. 2014;5(5):307–26.
Dziedzic T. Systemic inflammation as a therapeutic target in acute ischemic stroke. Expert Rev Neurother. 2015;15(5):523–31.
Zhang BJ, et al. Splenectomy protects experimental rats from cerebral damage after stroke due to anti-inflammatory effects. Chin Med J. 2013;126(12):2354–60.
Seifert HA, et al. The spleen contributes to stroke induced neurodegeneration through interferon gamma signaling. Metab Brain Dis. 2012;27(2):131–41.
Vendrame M, et al. Cord blood rescues stroke-induced changes in splenocyte phenotype and function. Exp Neurol. 2006;199(1):191–200.
Bang OY, et al. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005;57(6):874–82.
Diamandis T, Borlongan CV. One, two, three steps toward cell therapy for stroke. Stroke. 2015;46(2):588–91.
Bhasin A, et al. Stem cell therapy: a clinical trial of stroke. Clin Neurol Neurosurg. 2013;115(7):1003–8.
Prasad K, et al. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial. Stroke. 2014;45(12):3618–24.
Suarez-Monteagudo C, et al. Autologous bone marrow stem cell neurotransplantation in stroke patients. An open study. Restor Neurol Neurosci. 2009;27(3):151–61.
Honmou O, et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain. 2011;134(Pt 6):1790–807.
Banerjee S, et al. Intra-arterial immunoselected CD34+ stem cells for acute ischemic stroke. Stem Cells Transl Med. 2014;3(11):1322–30.
Jeong H, et al. Efficacy and safety of stem cell therapies for patients with stroke: a systematic review and single arm meta-analysis. Int J Stem Cells. 2014;7(2):63–9.
Horner RD, et al. Racial variations in ischemic stroke-related physical and functional impairments. Stroke. 1991;22(12):1497–501.
Imberti B, Monti M, Casiraghi F. Pluripotent stem cells and tolerance induction in organ transplantation. Curr Opin Organ Transplant. 2015;20(1):86–93.
Xin H, et al. Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells. 2012;30(7):1556–64.
Xin H, Li Y, Chopp M. Exosomes/miRNAs as mediating cell-based therapy of stroke. Front Cell Neurosci. 2014;8:377.
Zhang Y, et al. Effect of exosomes derived from multipluripotent mesenchymal stromal cells on functional recovery and neurovascular plasticity in rats after traumatic brain injury. J Neurosurg. 2015;122(4):856–67.
Chopp M, Zhang ZG. Emerging potential of exosomes and noncoding microRNAs for the treatment of neurological injury/diseases. Expert Opin Emerg Drugs. 2015;20(4):523–6.
Ban JJ, et al. Neurogenic effects of cell-free extracts of adipose stem cells. PLoS One. 2016;11(2):e0148691.
Cho YJ, et al. Therapeutic effects of human adipose stem cell-conditioned medium on stroke. J Neurosci Res. 2012;90(9):1794–802.
Tsai MJ, et al. Recovery of neurological function of ischemic stroke by application of conditioned medium of bone marrow mesenchymal stem cells derived from normal and cerebral ischemia rats. J Biomed Sci. 2014;21:5.
Egashira Y, et al. The conditioned medium of murine and human adipose-derived stem cells exerts neuroprotective effects against experimental stroke model. Brain Res. 2012;1461:87–95.
Doeppner TR, et al. Extracellular vesicles improve post-stroke neuroregeneration and prevent postischemic immunosuppression. Stem Cells Transl Med. 2015;4(10):1131–43.
Kalani A, et al. Curcumin-loaded embryonic stem cell exosomes restored neurovascular unit following ischemia-reperfusion injury. Int J Biochem Cell Biol. 2016;79:360–9.
Dela Pena I, et al. Stem cells and G-CSF for treating neuroinflammation in traumatic brain injury: aging as a comorbidity factor. J Neurosurg Sci. 2014;58(3):145–9.
Ribeiro CA, et al. The secretome of stem cells isolated from the adipose tissue and Wharton jelly acts differently on central nervous system derived cell populations. Stem Cell Res Ther. 2012;3(3):18.
Galindo LT, et al. Mesenchymal stem cell therapy modulates the inflammatory response in experimental traumatic brain injury. Neurol Res Int. 2011;2011:564089.
Blaber SP, et al. Analysis of in vitro secretion profiles from adipose-derived cell populations. J Transl Med. 2012;10:172.
Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21(6):354–61.
Zhang B, et al. The lncRNA Malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. Cell Rep. 2012;2(1):111–23.
Derrien T, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775–89.
Qi JH, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med. 2003;9(4):407–15.
Yao J, et al. Tissue inhibitor of matrix metalloproteinase-3 or vascular endothelial growth factor transfection of aged human mesenchymal stem cells enhances cell therapy after myocardial infarction. Rejuvenation Res. 2012;15(5):495–506.
Xin H, et al. MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles. Stem Cells. 2013;31(12):2737–46.
Jeong, H., et al., Efficacy and safety of stem cell therapies for patients with stroke: a systematic review and single arm meta-analysis. Int J Stem Cells, 2014. 7(2): p. 63–9.
Horner, R.D., et al., Racial variations in ischemic stroke-related physical and functional impairments. Stroke, 1991. 22(12): p. 1497–501.
Imberti, B., M. Monti, and F. Casiraghi, Pluripotent stem cells and tolerance induction in organ transplantation. Curr Opin Organ Transplant, 2015. 20(1): p. 86–93.
Xin, H., et al., Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells, 2012. 30(7): p. 1556–64.
Xin, H., Y. Li, and M. Chopp, Exosomes/miRNAs as mediating cell-based therapy of stroke. Front Cell Neurosci, 2014. 8: p. 377.
Zhang, Y., et al., Effect of exosomes derived from multipluripotent mesenchymal stromal cells on functional recovery and neurovascular plasticity in rats after traumatic brain injury. J Neurosurg, 2015. 122(4): p. 856–67.
Chopp, M. and Z.G. Zhang, Emerging potential of exosomes and noncoding microRNAs for the treatment of neurological injury/diseases. Expert Opin Emerg Drugs, 2015. 20(4): p. 523–6.
Ban, J.J., et al., Neurogenic Effects of Cell-Free Extracts of Adipose Stem Cells. PLoS One, 2016. 11(2): p. e0148691.
Cho, Y.J., et al., Therapeutic effects of human adipose stem cell-conditioned medium on stroke. J Neurosci Res, 2012. 90(9): p. 1794–802.
Tsai, M.J., et al., Recovery of neurological function of ischemic stroke by application of conditioned medium of bone marrow mesenchymal stem cells derived from normal and cerebral ischemia rats. J Biomed Sci, 2014. 21: p. 5.
Egashira, Y., et al., The conditioned medium of murine and human adipose-derived stem cells exerts neuroprotective effects against experimental stroke model. Brain Res, 2012. 1461: p. 87–95.
Doeppner, T.R., et al., Extracellular Vesicles Improve Post-Stroke Neuroregeneration and Prevent Postischemic Immunosuppression. Stem Cells Transl Med, 2015. 4(10): p. 1131–43.
Kalani, A., et al., Curcumin-loaded embryonic stem cell exosomes restored neurovascular unit following ischemia-reperfusion injury. Int J Biochem Cell Biol, 2016. 79: p. 360–369.
Dela Pena, I., et al., Stem cells and G-CSF for treating neuroinflammation in traumatic brain injury: aging as a comorbidity factor. J Neurosurg Sci, 2014. 58(3): p. 145–9.
Ribeiro, C.A., et al., The secretome of stem cells isolated from the adipose tissue and Wharton jelly acts differently on central nervous system derived cell populations. Stem Cell Res Ther, 2012. 3(3): p. 18.
Galindo, L.T., et al., Mesenchymal stem cell therapy modulates the inflammatory response in experimental traumatic brain injury. Neurol Res Int, 2011. 2011: p. 564089.
Blaber, S.P., et al., Analysis of in vitro secretion profiles from adipose-derived cell populations. J Transl Med, 2012. 10: p. 172.
Wapinski, O. and H.Y. Chang, Long noncoding RNAs and human disease. Trends Cell Biol, 2011. 21(6): p. 354–61.
Zhang, B., et al., The lncRNA Malat1 is dispensable for mouse development but its transcription plays a cisregulatory role in the adult. Cell Rep, 2012. 2(1): p. 111–23.
Derrien, T., et al., The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res, 2012. 22(9): p. 1775–89.
Qi, J.H., et al., A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med, 2003. 9(4): p. 407–15.
Yao, J., et al., Tissue inhibitor of matrix metalloproteinase-3 or vascular endothelial growth factor transfection of aged human mesenchymal stem cells enhances cell therapy after myocardial infarction. Rejuvenation Res, 2012. 15(5): p. 495–506.
Xin, H., et al., MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles. Stem Cells, 2013. 31(12): p. 2737–46.
Editors and Affiliations
Rights and permissions
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Crowley, M.G., Grant Liska, M., Borlongan, C.V. (2017). Stem Cell Therapy for Neurovascular and Traumatic Brain Diseases. In: Emerich, D., Orive, G. (eds) Cell Therapy. Molecular and Translational Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-319-57153-9_3
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-57152-2
Online ISBN: 978-3-319-57153-9
eBook Packages: MedicineMedicine (R0)